WO2018169282A3 - Atpif1을 함유하는 당뇨 치료용 약학조성물 - Google Patents

Atpif1을 함유하는 당뇨 치료용 약학조성물 Download PDF

Info

Publication number
WO2018169282A3
WO2018169282A3 PCT/KR2018/002933 KR2018002933W WO2018169282A3 WO 2018169282 A3 WO2018169282 A3 WO 2018169282A3 KR 2018002933 W KR2018002933 W KR 2018002933W WO 2018169282 A3 WO2018169282 A3 WO 2018169282A3
Authority
WO
WIPO (PCT)
Prior art keywords
composition containing
treatment
diabetes
pharmaceutical composition
atpif1
Prior art date
Application number
PCT/KR2018/002933
Other languages
English (en)
French (fr)
Other versions
WO2018169282A2 (ko
Inventor
김현수
Original Assignee
고려대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 고려대학교 산학협력단 filed Critical 고려대학교 산학협력단
Priority to EP18768521.9A priority Critical patent/EP3597208B1/en
Priority to US16/494,293 priority patent/US10946060B2/en
Priority to CN201880026184.5A priority patent/CN110536692B/zh
Publication of WO2018169282A2 publication Critical patent/WO2018169282A2/ko
Publication of WO2018169282A3 publication Critical patent/WO2018169282A3/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

본 발명은 ATPIF1(ATPase inhibitor factor 1)을 유효성분으로 함유하는 당뇨 또는 당뇨 합병증의 예방 또는 치료용 약학 조성물 및 ATPIF1을 유효성분으로 함유하는 비만의 예방 또는 치료용 약학 조성물에 관한으로, 본 발명에 따른 ATPIF1을 함유하는 조성물은 근육세포에서의 당 흡수를 촉진하고 인슐린 민감성을 향상시켜 당뇨 치료효과를 가지며, 지방세포에서 지방합성을 억제하고 지방세포의 갈색화를 촉진하는 효과를 가지고 있어, 비만을 예방 또는 치료하는 효과를 가진다.
PCT/KR2018/002933 2017-03-17 2018-03-13 Atpif1을 함유하는 당뇨 치료용 약학조성물 WO2018169282A2 (ko)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP18768521.9A EP3597208B1 (en) 2017-03-17 2018-03-13 Pharmaceutical composition containing atpif1 for treatment of diabetes
US16/494,293 US10946060B2 (en) 2017-03-17 2018-03-13 Pharmaceutical composition containing ATPIF1 for treatment of diabetes
CN201880026184.5A CN110536692B (zh) 2017-03-17 2018-03-13 用于治疗糖尿病的含有atpif1的药物组合物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2017-0033742 2017-03-17
KR1020170033742A KR101941975B1 (ko) 2017-03-17 2017-03-17 Atpif1을 함유하는 당뇨 치료용 약학조성물

Publications (2)

Publication Number Publication Date
WO2018169282A2 WO2018169282A2 (ko) 2018-09-20
WO2018169282A3 true WO2018169282A3 (ko) 2019-01-10

Family

ID=63522400

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/002933 WO2018169282A2 (ko) 2017-03-17 2018-03-13 Atpif1을 함유하는 당뇨 치료용 약학조성물

Country Status (5)

Country Link
US (1) US10946060B2 (ko)
EP (1) EP3597208B1 (ko)
KR (1) KR101941975B1 (ko)
CN (1) CN110536692B (ko)
WO (1) WO2018169282A2 (ko)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108250290B (zh) * 2018-02-23 2024-03-12 上海捌加壹医药科技有限公司 Ccr4的n端重组蛋白及其用途
KR102276379B1 (ko) * 2018-10-02 2021-07-14 고려대학교 산학협력단 IF1 (ATPase inhibitory factor 1)을 유효성분으로 함유하는 골질환의 예방 또는 치료용 약학 조성물
WO2021123300A1 (en) * 2019-12-20 2021-06-24 Lifesearch Treatment of hepatic and cardiovascular disorders
KR20220090474A (ko) * 2020-12-22 2022-06-29 (주)메디엔진 알코올성 및 비알코올성 지방간의 예방 또는 치료용 약학 조성물
KR20220090473A (ko) * 2020-12-22 2022-06-29 (주)메디엔진 신규한 펩타이드 및 이의 용도
CN117858716A (zh) * 2021-06-28 2024-04-09 高丽大学校产学协力团 具有肥胖症和肌肉损失抑制活性的肽及其用途
AU2022300553A1 (en) * 2021-06-28 2024-01-18 Medi&Gene Inc. Peptide having antidiabetic activity and use thereof
KR20230160738A (ko) * 2022-05-16 2023-11-24 고려대학교 산학협력단 혈뇌장벽을 통과하는 폴리펩타이드 및 이의 용도

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040072739A1 (en) * 1999-11-10 2004-04-15 Anderson Christen M. Compositions and methods for regulating endogenous inhibitor of ATP synthase, including treatment for diabetes
US20150065556A1 (en) * 2013-08-05 2015-03-05 Whitehead Institute For Biomedical Research Therapeutic targets for mitochondrial disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
WO1997034631A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
WO1998033909A1 (en) * 1997-01-31 1998-08-06 Incyte Pharmaceuticals, Inc. Novel human atpase inhibitor protein
US20020091081A1 (en) * 2000-08-22 2002-07-11 Papathanassiu Adonia E. Compositions and methods for inhibiting angiogenesis
JP2008169195A (ja) 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
AR081066A1 (es) 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
KR101324828B1 (ko) 2010-06-08 2013-11-01 한미사이언스 주식회사 면역글로불린 단편을 이용한 단쇄 인슐린 아날로그 약물 결합체
KR101330868B1 (ko) 2010-06-08 2013-11-18 한미사이언스 주식회사 면역글로불린 단편을 이용한 인슐린 유도체 약물 결합체
MY180513A (en) 2011-03-02 2020-12-01 Oerlikon Surface Solutions Ag Trubbach Sliding component coated with metal-comprising carbon layer for improving wear and friction behavior by tribological applications under lubricated conditions
WO2012150164A1 (en) 2011-05-03 2012-11-08 Teijin Aramid B.V. Antiballistic panel
CN114989289A (zh) 2013-02-26 2022-09-02 韩美药品株式会社 新颖的胰岛素类似物及其用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040072739A1 (en) * 1999-11-10 2004-04-15 Anderson Christen M. Compositions and methods for regulating endogenous inhibitor of ATP synthase, including treatment for diabetes
US20150065556A1 (en) * 2013-08-05 2015-03-05 Whitehead Institute For Biomedical Research Therapeutic targets for mitochondrial disorders

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FORMENTINI, LAURA ET AL.: "Mitochondrial H+-ATP Synthase in Human Skeletal Muscle: Contribution to Dyslipidaemia and Insulin Resistance", DIABETOLOGIA, vol. 60, no. 10, 2 August 2017 (2017-08-02), pages 2052 - 2065, XP036614424 *
GARCIA-BERMUDEZ, JAVIER ET AL.: "The ATPase Inhibitor Factor I (IF1): A Master Regulator of Energy Metabolism and of Cell Survival", BIOCHIMICA ET BIOPHYSICA ACTA (BBA)-BIOENERGETICS, vol. 1857, no. 8, 2016, pages 1167 - 1182, XP029566616 *
GENOUX, ANNELISE ET AL.: "Mitochondrial Inhibitory Factor 1 (IF1) Is Present in Human Serum and Is Positively Correlated with HDL-cholesterol", PLOS ONE, vol. 6, no. 9, 14 September 2011 (2011-09-14), pages e23949, XP055561582 *
GENOUX, ANNELISE ET AL.: "Serum Levels of Mitochondrial Inhibitory Factor ! Are Independently Associated with Long-term Prognosis in Coronary Artery Disease: the GENES Study", BMC MEDICINE, vol. 14, 2016, pages 1 - 10, XP055561584 *

Also Published As

Publication number Publication date
US20200129581A1 (en) 2020-04-30
WO2018169282A2 (ko) 2018-09-20
EP3597208A2 (en) 2020-01-22
US10946060B2 (en) 2021-03-16
KR20180107368A (ko) 2018-10-02
EP3597208B1 (en) 2022-10-19
KR101941975B1 (ko) 2019-01-25
EP3597208A4 (en) 2020-12-16
CN110536692B (zh) 2023-04-14
CN110536692A (zh) 2019-12-03

Similar Documents

Publication Publication Date Title
WO2018169282A3 (ko) Atpif1을 함유하는 당뇨 치료용 약학조성물
PH12018500767A1 (en) Pharmaceutical composition, methods for treating and uses thereof
WO2014195966A3 (en) Amorphous form of canagliflozin and process for preparing thereof
MY159058A (en) Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agent
MX2013004699A (es) Combinaciones farmaceuticas para el tratamiento de trastornos metabolicos.
MX2012006734A (es) Tiazolidinadionas moderadoras de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de obesidad y otras enfermedades metabolicas.
EA201590759A1 (ru) Композиция для лечения диабета или диажирения, содержащая аналог оксинтомодулина
MX2015008114A (es) Derivados de exendina-4.
WO2007084314A3 (en) MODULATORS OF 11-ß HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
WO2015128403A3 (en) An a22k, desb27, b29r, des b30, at epsilon position of lysine 22 acylated human insulin analogue
IN2014KN02830A (ko)
MX2015013275A (es) Composiciones que comprenden selenio y uso de las mismas para el tratamiento y prevencion de enfermedades o afecciones asociadas con difucion mitocondrial.
WO2018093238A3 (ko) 포름산 생성능이 우수한 균주를 유효성분으로 포함하는 비만 또는 비만으로 야기된 대사증후군의 예방 또는 치료용 조성물
WO2015095354A3 (en) Compositions and methods for treating fatty tissue buildup
WO2011163319A3 (en) Activation of amp-protein activated kinase by oxaloacetate compounds
EA033540B1 (ru) Композиция, включающая окру, для применения в уменьшении абсорбции пищевого жира
WO2016190566A3 (ko) 아위버섯 물 추출물을 유효성분으로 함유하는 대사성질환의 예방 및 치료용 약학적 조성물 또는 건강기능성식품
WO2016085321A3 (en) Composition comprising a pentose and polyphenolic compound
WO2018093237A3 (ko) 포름산 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 비만 또는 비만으로 야기된 대사증후군의 예방 또는 치료용 조성물
WO2011052935A3 (ko) 토복령, 여주 및 동충하초 추출물을 유효성분으로 포함하는 혈당 강하용 조성물
PH12020550050A1 (en) Novel acylated insulin analogues and uses thereof
WO2011126342A3 (ko) 대잎둥굴레 또는 층층갈고리둥굴레 추출물의 신규한 용도
MX337606B (es) Metodo y composiciones farmaceuticas para el tratamiento de la hiperglicemia postprandial de la diabetes tipo ii, a traves de la mucosa bucal.
EA201290485A1 (ru) Производные бензамида
WO2012138146A3 (ko) 돌콩의 열처리분말 또는 추출물을 유효성분으로 하는 당뇨병 및 당뇨합병증의 예방 및 치료를 위한 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18768521

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2018768521

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2018768521

Country of ref document: EP

Effective date: 20191017